Investigators reported results from the first randomized controlled trial of office-based laser photocoagulation to standard TURBT for low-grade Ta bladder tumors.

President and CEO Liz Barrett outlined the company’s urothelial cancer focus and provided an update on the commercial launch of its recently approved bladder cancer therapy during a fireside chat. RTG ...

Protara Therapeutics, Inc. TARA shares are down during Tuesday’s premarket session following the release of updated interim ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor ...

The company is on track to initiate the Advanced-3 registrational trial in patients who have not previously received BCG in ...

ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will ...

The mother of a 3-year-old boy who died of fentanyl poisoning must remain in the Napa County jail ahead of a murder trial, a judge ruled — and the child’s father, also charged ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report ...

ImmunityBio partner Accord Healthcare to deploy an 85-person sales force to drive ANKTIVA commercialization across 30 countries -- Dublin-based subsidiary to support ImmunityBio's distribution and ...

ImmunityBio partner Accord Healthcare to deploy an 85-person sales force to drive ANKTIVA commercialization across 30 countriesDublin-based subsidiary to support ImmunityBio’s distribution and ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor ...